Limaprost is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency. Limaprost is an inhibitor of ADP and collagen-induced platelet aggregation and is 10-1,000 times more potent than PGE1 as an inhibitor of platelet adhesiveness measured in vitro. 3-methoxy Limaprost results from the Michael addition of methanol to the limaprost 2,3 double bond. The resulting novel compound is likely to retain FP receptor agonist activity; however there are no published studies of the pharmacological properties of 3-methoxy limaprost.